

What is claimed is:

1. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase.

5 2. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form A.

3. The crystalline polymorph of Claim 2, wherein said polymorph has an XRPD pattern substantially the same as Figure 1.

10 4. The crystalline polymorph of Claim 2 or 3, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 20.3.

5. The crystalline polymorph of any one of Claims 2 to 4, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 19.1,
15 20.3, 21.9, 23.1 and 25.2.

6. A process for preparing the crystalline polymorph of any one of Claims 2 to 5, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 1:1
20 EtOH:water; and

(b) recrystallizing the solid to prepare Form A.

7. The process of Claim 6, wherein the mixture in Step (a) is heated.

8. The process of Claims 6 or 7, wherein the mixture in Step (a) is heated to about 50°C.

25 9. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B.

10. The crystalline polymorph of Claim 9, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 9.9 and 25.5.

30 11. The crystalline polymorph of Claims 9 or 10, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 9.9, 16.9, 18.0, 20.7 and 25.5.

12. A process for preparing the crystalline polymorph of any one of Claims 9 to 11, comprising:

(a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E with a solvent selected from MeOH, or

(a2) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from MeOH, acetone and DCM, or

(a3) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with a solvent selected from EtOH, or

(a4) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with a solvent selected from IPA,

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the solvent, and

(c) recrystallizing the solid to prepare Form B; or

(d1) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN, or

(d2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF, and

(e) recrystallizing the solid to prepare Form B; or

(f) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, and

(g) recovering the solid to prepare Form B.

13. The process of Claim 12, wherein the solution in Step (b) is created by heating the mixture of Step (a2) or (a4) to reflux.

14. The process of Claim 12, wherein the solution in Step (b) is created by using EtOH as the solvent and heating the mixture of Step (a3) to about 70°C.

15. The process of Claim 12, wherein the heating in Step (f) is done at about 100 to about 200°C.

16. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Methanol.

17. The crystalline polymorph of Claim 16, wherein said polymorph has an XRPD pattern substantially the same as Figure 2.

18. The crystalline polymorph of Claim 16 or 17, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 10.0.

19. The crystalline polymorph of any one of Claims 16 to 18, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 8.5, 10.0, 13.4, 17.0 and 25.5.

20. A process for preparing the crystalline polymorph of any one of Claims 16 to 19, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine with MeOH;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOH; and

(c) recrystallizing the solid to prepare Form B Methanol.

21. The process of Claim 20, wherein the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

22. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Ethanol.

23. The crystalline polymorph of Claim 22, wherein said polymorph has an XRPD pattern substantially the same as Figure 3.

24. The crystalline polymorph of Claim 22 or 23, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 25.4.

25. The crystalline polymorph of any one of Claims 22 to 24, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 9.9, 13.3, 20.7, 24.6 and 25.4.

26. A process for preparing the crystalline polymorph of any one of Claims 22 to 25, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with EtOH;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOH; and

(c) recrystallizing the solid to prepare Form B Ethanol.

27. The process of Claim 26, wherein the solution in Step (b) is created by heating the mixture of Step (a) to about 70°C.

28. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Isopropyl Alcohol.

29. The crystalline polymorph of Claim 28, wherein said polymorph has an XRPD pattern substantially the same as Figure 4.

30. The crystalline polymorph of Claim 28 or 29, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.9.

31. The crystalline polymorph of any one of Claims 28 to 30, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 9.8, 16.9, 17.9, 20.6 and 25.1.

32. A process for preparing the crystalline polymorph of any one of Claims 28 to 31, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with IPA;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and IPA; and

(c) recrystallizing the solid to prepare Form B Isopropyl Alcohol.

33. The process of Claim 32, wherein the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

34. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Acetonitrile.

35. The crystalline polymorph of Claim 34, wherein said polymorph has an XRPD pattern substantially the same as Figure 5.

36. The crystalline polymorph of Claim 34 or 35, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 25.7.

37. The crystalline polymorph of any one of Claims 34 to 36, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 10.0, 13.5, 16.9, 24.9 and 25.7.

38. A process for preparing the crystalline polymorph of any one of Claims 34 to 37, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN; and

(b) recrystallizing the solid to prepare Form B Acetonitrile.

39. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Acetone.

40. The crystalline polymorph of Claim 39, wherein said polymorph has an XRPD pattern substantially the same as Figure 6.

41. The crystalline polymorph of Claim 39 or 40, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.9.

42. The crystalline polymorph of any one of Claims 39 to 41, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 9.9, 17.0, 18.0, 24.7 and 25.5.

43. A process for preparing the crystalline polymorph of any one of Claims 39 to 42, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone; and

(c) recrystallizing the solid to prepare Form B Acetone.

44. The process of Claim 43, wherein the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

45. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Dichloromethane.

46. The crystalline polymorph of Claim 45, wherein said polymorph has an XRPD pattern substantially the same as Figure 7.

47. The crystalline polymorph of Claim 45 or 46, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.9.

48. The crystalline polymorph of any one of Claims 45 to 47, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 10.0, 13.4, 16.9, 20.7 and 25.6.

49. A process for preparing the crystalline polymorph of any one of Claims 45 to 48, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM; and

(c) recrystallizing the solid to prepare Form B Dichloromethane.

50. The process of Claim 49, wherein the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

51. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Tetrahydrofuran.

52. The crystalline polymorph of Claim 51, wherein said polymorph has an XRPD pattern substantially the same as Figure 8.

53. The crystalline polymorph of Claim 51 or 52, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 25.4.

54. The crystalline polymorph of any one of Claims 51 to 53, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 9.8, 16.7, 17.9, 24.7 and 25.4.

55. A process for prepping the crystalline polymorph of any one of Claims 51 to 54, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF; and

(b) recrystallizing the solid to prepare Form B Tetrahydrofuran.

56. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form B Anhydrous.

57. The crystalline polymorph of Claim 56, wherein said polymorph has an XRPD pattern substantially the same as Figure 9.

58. The crystalline polymorph of Claim 56 or 57, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 9.9.

59. The crystalline polymorph of any one of Claims 56 to 58, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 9.9, 13.6, 18.1, 21.5 and 25.5.

60. A process for preparing the crystalline polymorph of any one of Claims 56 to 59, comprising:

(a) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B; and

(b) recovering the solid to prepare Form B Anhydrous.

61. The process of Claim 60, wherein the heating in Step (a) is done at about 100 to about 200°C.

62. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form C.

63. The crystalline polymorph of Claim 62, wherein said polymorph has an XRPD pattern substantially the same as Figure 10.

64. The crystalline polymorph of Claim 62 or 63, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 5.0.

65. The crystalline polymorph of any one of Claims 62 to 64, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 5.0, 14.4, 15.3, 18.4 and 18.9.

66. A process for preparing the crystalline polymorph of any one of Claims 62 to 65, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and 2-methoxyethanol;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(c) recrystallizing the solid to prepare Form C.

67. The process of Claim 66, wherein the solution in Step (b) is created by heating the mixture of Step (a) to about 50°C.

68. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form D.

69. The crystalline polymorph of Claim 68, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.3) at about 8.0 and 12.7.

70. The crystalline polymorph of Claims 68 or 69, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.3) at about 8.0, 9.8, 11.3, 12.6, 13.9, 16.2, 17.2 and 19.7.

71. A process for preparing the crystalline polymorph of any one of Claims 68 to 70, comprising:

(a1) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from EtOAc, dioxane and propyl acetate, or

(a2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and a solvent selected from acetone and propyl acetate, and

(b) recrystallizing the solid to prepare Form D.

72. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form D Ethyl Acetate.

73. The crystalline polymorph of Claim 72, wherein said polymorph has an XRPD pattern substantially the same as Figure 11.

74. The crystalline polymorph of Claim 72 or 73, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

75. The crystalline polymorph of any one of Claims 72 to 74, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 8.0, 12.7, 16.1, 17.1 and 19.8.

76. A process for preparing the crystalline polymorph of any one of Claims 72 to 75, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOAc; and

(b) recrystallizing the solid to prepare Form D Ethyl Acetate.

77. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form D Dioxane.

78. The crystalline polymorph of Claim 77, wherein said polymorph has an XRPD pattern substantially the same as Figure 12.

79. The crystalline polymorph of Claim 77 or 78, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 19.5.

80. The crystalline polymorph of any one of Claims 77 to 79, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.8, 11.1, 12.5, 19.5 and 23.1.

81. A process for preparing the crystalline polymorph of any one of Claims 77 to 80, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and dioxane; and

(b) recrystallizing the solid to prepare Form D Dioxane.

82. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form D Acetone.

83. The crystalline polymorph of Claim 82, wherein said polymorph has an XRPD pattern substantially the same as Figure 13.

84. The crystalline polymorph of Claim 82 or 83, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

85. The crystalline polymorph of any one of Claims 82 to 84, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 8.0, 17.1, 21.4, 23.6 and 27.5.

86. A process for preparing the crystalline polymorph of any one of Claims 82 to 85, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and acetone; and

(b) recrystallizing the solid to prepare Form D Acetone.

87. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form D Propyl Acetate.

88. The crystalline polymorph of Claim 87, wherein said polymorph has an XRPD pattern substantially the same as Figure 14.

89. The crystalline polymorph of Claim 87 or 88, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

90. The crystalline polymorph of any one of Claims 87 to 89, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 8.0, 12.7, 16.1, 17.1 and 19.8.

91. A process for preparing the crystalline polymorph of any one of Claims 87 to 90, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and propyl acetate; and

(b) recrystallizing the solid to prepare Form D Propyl Acetate.

92. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form E.

93. The crystalline polymorph of Claim 92, wherein said polymorph has an XRPD pattern substantially the same as Figure 15.

94. The crystalline polymorph of Claim 92 or 93, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.1.

95. The crystalline polymorph of any one of Claims 92 to 94, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 8.7, 9.4, 11.9, 16.1 and 23.7.

96. A process for preparing the crystalline polymorph of any one of Claims 92 to 94, comprising:

(a) mixing 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea in THF under basic conditions;

(b) adding water to the mixture to form an oil of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine;

(c) recovering the product as *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E.

97. The process of Claim 96, wherein the basic conditions in Step (a) are provided by 2.5N NaOH.

98. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form F.

99. The crystalline polymorph of Claim 98, wherein said polymorph has an XRPD pattern substantially the same as Figure 16.

5 100. The crystalline polymorph of Claim 98 or 99, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 16.6.

101. The crystalline polymorph of any one of Claims 98 to 100, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 14.9,
10 16.6, 16.9, 19.1 and 21.2.

102. A process for preparing the crystalline polymorph of any one of Claims 98 to 101, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and ethyl acetate;
15 and

(b) recrystallizing the solid to prepare Form F.

103. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form G.

20 104. The crystalline polymorph of Claim 103, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.3) at about 7.8 and 23.2.

105. The crystalline polymorph of Claims 103 or 104, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.3) at about 7.8, 11.2 and 23.2.

106. The crystalline polymorph of any one of Claims 103 to 105, wherein said
25 polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.3) at about 7.8, 8.1, 9.3, 11.2, 16.6, 23.2, 24.3 and 27.6.

107. A process for preparing the crystalline polymorph of any one of Claims 103 to 106, comprising:

(a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-
30 Tetrahydrofuran and 20:80 THF:water, or

(a2) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-

dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from isopropyl acetate and MIBK, and

(b) recrystallizing the solid to prepare Form G; or

(c) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran,

(d) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF, and

(e) recrystallizing the solid to prepare Form G.

108. The process of Claim 107, wherein the solution in Step (d) is created by heating the mixture of Step (c) to reflux.

109. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form G hemi-Tetrahydrofuran.

110. The crystalline polymorph of Claim 109, wherein said polymorph has an XRPD pattern substantially the same as Figure 17.

111. The crystalline polymorph of Claim 109 or 110, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.1.

112. The crystalline polymorph of any one of Claims 109 to 111, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.7, 11.1, 12.3, 23.1 and 24.1.

113. A process for preparing the crystalline polymorph of any one of Claims 109 to 112, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water; and

(b) recrystallizing the solid to prepare Form G hemi-Tetrahydrofuran.

114. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form G mono-Tetrahydrofuran.

115. The crystalline polymorph of Claim 114, wherein said polymorph has an XRPD pattern substantially the same as Figure 18.

116. The crystalline polymorph of Claim 114 or 115, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.1.

117. The crystalline polymorph of any one of Claims 114 to 116, wherein said
5 polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.7, 11.1, 12.4, 23.0 and 24.0.

118. A process for preparing the crystalline polymorph of any one of Claims 114 to 117, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

15 (c) recrystallizing the solid to prepare Form G mono-Tetrahydrofuran.

119. The process of Claim 118, wherein the solution in Step (b) is created by heating the mixture of Step (a) to reflux.

120. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form
20 G Isopropyl Acetate.

121. The crystalline polymorph of Claim 120, wherein said polymorph has an XRPD pattern substantially the same as Figure 19.

122. The crystalline polymorph of Claim 120 or 121, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about
25 23.4.

123. The crystalline polymorph of any one of Claims 120 to 122, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.8, 8.3, 11.4, 13.2 and 23.4.

124. A process for preparing the crystalline polymorph of any one of Claims 120 to 123, comprising:
30

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and isopropyl acetate; and

(b) recrystallizing the solid to prepare Form G Isopropyl Acetate.

125. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form G Methyl Isobutyl Ketone.

5 126. The crystalline polymorph of Claim 125, wherein said polymorph has an XRPD pattern substantially the same as Figure 20.

127. The crystalline polymorph of Claim 125 or 126, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.3.

10 128. The crystalline polymorph of any one of Claims 125 to 127, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.8, 8.2, 11.2, 16.5 and 23.2.

129. A process for preparing the crystalline polymorph of any one of Claims 125 to 128, comprising:

15 (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MIBK; and

(b) recrystallizing the solid to prepare Form G Methyl Isobutyl Ketone.

20 130. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form H.

131. The crystalline polymorph of Claim 130, wherein said polymorph has an XRPD pattern substantially the same as Figure 21.

25 132. The crystalline polymorph of Claim 130 or 131, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 11.2.

133. The crystalline polymorph of any one of Claims 130 to 132, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 11.2, 16.1, 19.6, 22.0 and 25.5.

30 134. A process for preparing the crystalline polymorph of any one of Claims 130 to 133, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MTBE; and

(b) recrystallizing the solid to prepare Form H.

5 135. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form I.

136. The crystalline polymorph of Claim 135, wherein said polymorph has an XRPD pattern substantially the same as Figure 22.

10 137. The crystalline polymorph of Claim 135 or 136, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 7.2.

138. The crystalline polymorph of any one of Claims 135 to 137, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 7.2, 16.6, 18.3, 22.3 and 23.1.

15 139. A process for preparing the crystalline polymorph of any one of Claims 135 to 138, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and xylene; and

20 (b) recrystallizing the solid to prepare Form I.

140. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form J.

141. The crystalline polymorph of Claim 140, wherein said polymorph has an XRPD pattern substantially the same as Figure 23.

25 142. The crystalline polymorph of Claim 140 or 141, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 17.0.

30 143. The crystalline polymorph of any one of Claims 140 to 142, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 4.5, 9.0, 17.0, 18.0 and 18.8.

144. A process for preparing the crystalline polymorph of any one of Claims 140 to 143, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E

or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(b) recrystallizing the solid to prepare Form J.

145. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form K.

146. The crystalline polymorph of Claim 145, wherein said polymorph has an XRPD pattern substantially the same as Figure 24.

147. The crystalline polymorph of Claim 145 or 146, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 22.8.

148. The crystalline polymorph of any one of Claims 145 to 147, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 15.8, 17.6, 22.8, 23.0 and 25.7.

149. A process for preparing the crystalline polymorph of any one of Claims 145 to 148, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DME; and

(b) recrystallizing the solid to prepare Form K.

150. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form L.

151. The crystalline polymorph of Claim 150, wherein said polymorph has an XRPD pattern substantially the same as Figure 25.

152. The crystalline polymorph of Claim 150 or 151, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 17.0.

153. The crystalline polymorph of any one of Claims 150 to 152, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees ± 0.2) at about 14.9, 17.0, 19.0, 21.1 and 22.5.

154. A process for preparing the crystalline polymorph of any one of Claims 150 to 153, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOAc; and

5 (b) recrystallizing the solid to prepare Form L.

155. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form M.

156. The crystalline polymorph of Claim 155, wherein said polymorph has an
10 XRPD pattern substantially the same as Figure 26.

157. The crystalline polymorph of Claim 155 or 156, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.0.

158. The crystalline polymorph of any one of Claims 155 to 157, wherein said
15 polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 9.0, 15.1, 20.7, 23.1 and 26.8.

159. A process for preparing the crystalline polymorph of any one of Claims 155 to 158, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-
20 (4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and 1:1 THF:water; and

(b) recrystallizing the solid to prepare Form M.

160. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form
25 N.

161. The crystalline polymorph of Claim 160, wherein said polymorph has an XRPD pattern substantially the same as Figure 27.

162. The crystalline polymorph of Claim 160 or 161, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about
30 22.9.

163. The crystalline polymorph of any one of Claims 160 to 162, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 15.9, 17.8, 19.2, 22.9 and 25.9.

164. A process for preparing the crystalline polymorph of any one of Claims 160 to 163, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and a solution of 1% sodium carboxymethyl cellulose, 0.1% Tween® in water; and

(b) recrystallizing the solid to prepare Form N.

165. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form O.

166. The crystalline polymorph of Claim 165, wherein said polymorph has an XRPD pattern substantially the same as Figure 28.

167. The crystalline polymorph of Claim 165 or 166, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 11.2.

168. The crystalline polymorph of any one of Claims 165 to 167, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 11.2, 16.5, 20.0, 22.2 and 25.6.

169. A process for preparing the crystalline polymorph of any one of Claims 165 to 168, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran with THF;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

(c) recrystallizing the solid to prepare Form O.

170. The process of Claim 169, wherein the solution in Step (b) is created by heating the mixture of Step (a) to about 50°C.

171. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Form P.

172. The crystalline polymorph of Claim 171, wherein said polymorph has an XRPD pattern substantially the same as Figure 29.

173. The crystalline polymorph of Claim 171 or 172, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.5.

174. The crystalline polymorph of any one of Claims 171 to 173, wherein said
5 polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.2) at about 9.9, 13.7, 15.7, 17.7 and 23.5.

175. A process for preparing the crystalline polymorph of any one of Claims 171 to 174, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-
10 (4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Tetrahydrofuran with water; and

(b) recrystallizing the solid to prepare Form P.

176. Amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.

15 177. The amorphous polymorph of Claim 176, wherein said polymorph has an XRPD pattern substantially the same as Figure 30.

178. A process for preparing the amorphous polymorph of any one of Claims 176 to 177, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-
20 (4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol with 3:7 water:THF;

(b) sonicating the solution of Step (a);

(c) freezing and lyophilizing the solution to prepare amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-
25 dihydrooxazol-2-yl)quinazoline-4,6-diamine.

179. A pharmaceutical composition comprising a compound of any one of Claims 1 to 5, 9 to 11, 16 to 19, 22 to 25, 28 to 31, 34 to 37, 39 to 42, 45 to 48, 51 to 54, 56 to 59, 62 to 65, 68 to 70, 72 to 75, 77 to 80, 82 to 85, 87 to 90, 92 to 95, 98 to 101, 103 to 106, 109 to 112, 114 to 117, 120 to 123, 125 to 128, 130 to 133, 135 to 138, 140 to 143,
30 145 to 148, 150 to 153, 155 to 158, 160 to 163, 165 to 168, 171 to 174, 176 or 177, and a pharmaceutically acceptable carrier or excipient.

180. A method of preventing or treating a disease or disorder modulated by ErbB2, comprising administering to a mammal in need of such treatment an effective amount of a compound of any one of Claims 1 to 5, 9 to 11, 16 to 19, 22 to 25, 28 to 31,

34 to 37, 39 to 42, 45 to 48, 51 to 54, 56 to 59, 62 to 65, 68 to 70, 72 to 75, 77 to 80, 82 to 85, 87 to 90, 92 to 95, 98 to 101, 103 to 106, 109 to 112, 114 to 117, 120 to 123, 125 to 128, 130 to 133, 135 to 138, 140 to 143, 145 to 148, 150 to 153, 155 to 158, 160 to 163, 165 to 168, 171 to 174, 176 or 177.

5 181. A method of treating a hyperproliferative disease in a mammal comprising administering a therapeutically effective amount of a compound of Claims 1 to 5, 9 to 11, 16 to 19, 22 to 25, 28 to 31, 34 to 37, 39 to 42, 45 to 48, 51 to 54, 56 to 59, 62 to 65, 68 to 70, 72 to 75, 77 to 80, 82 to 85, 87 to 90, 92 to 95, 98 to 101, 103 to 106, 109 to 112, 114 to 117, 120 to 123, 125 to 128, 130 to 133, 135 to 138, 140 to 143, 145 to 148, 150 to 153, 10 155 to 158, 160 to 163, 165 to 168, 171 to 174, 176 or 177 to the mammal.

182. The method of Claim 181, wherein the hyperproliferative disease is cancer.

183. The method of Claim 182, wherein the cancer is ErbB2 positive.

184. The method of Claims 182 or 183, wherein the cancer is selected from breast, gastric, biliary, colorectal, brain, lung, NSCLC, pancreatic, head and neck, ovarian 15 and uterine cancer.

185. The method of any one of Claims 180 to 184, wherein one or more additional compounds having anti-cancer properties are administered in combination.

186. Use of a compound of any one of Claims 1 to 5, 9 to 11, 16 to 19, 22 to 25, 28 to 31, 34 to 37, 39 to 42, 45 to 48, 51 to 54, 56 to 59, 62 to 65, 68 to 70, 72 to 75, 77 to 20 80, 82 to 85, 87 to 90, 92 to 95, 98 to 101, 103 to 106, 109 to 112, 114 to 117, 120 to 123, 125 to 128, 130 to 133, 135 to 138, 140 to 143, 145 to 148, 150 to 153, 155 to 158, 160 to 163, 165 to 168, 171 to 174, 176 or 177 in the manufacture of a medicament for the treatment of a hyperproliferative disease.

187. The use of Claim 186, wherein the hyperproliferative disease is cancer.

25 188. The use of Claim 187, wherein the cancer is ErbB2 positive.

189. The use of Claims 187 or 188, wherein the cancer is selected from breast, gastric, biliary, colorectal, brain, lung, NSCLC, pancreatic, head and neck, ovarian and uterine cancer.

190. The use of any one of Claims 186 to 189, wherein one or more additional 30 compounds having anti-cancer properties are administered in combination.

191. The compound of any one of Claims 1 to 5, 9 to 11, 16 to 19, 22 to 25, 28 to 31, 34 to 37, 39 to 42, 45 to 48, 51 to 54, 56 to 59, 62 to 65, 68 to 70, 72 to 75, 77 to 80, 82 to 85, 87 to 90, 92 to 95, 98 to 101, 103 to 106, 109 to 112, 114 to 117, 120 to 123, 125

to 128, 130 to 133, 135 to 138, 140 to 143, 145 to 148, 150 to 153, 155 to 158, 160 to 163, 165 to 168, 171 to 174, 176 or 177 for the treatment of disease.

192. The compound of Claim 191, wherein the disease is a hyperproliferative disease.

5 193. The compound of Claim 192, wherein the hyperproliferative disease is cancer.

194. The compound of Claim 193, wherein the cancer is ErbB2 positive.

195. The compound of Claims 193 or 194, wherein the cancer is selected from breast, gastric, biliary, colorectal, brain, lung, NSCLC, pancreatic, head and neck, ovarian
10 and uterine cancer.

196. The compound of any one of Claims 191 to 195, wherein one or more additional compounds having anti-cancer properties are administered in combination.

CLAIMS

1. A crystalline polymorph of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine freebase.
2. The crystalline polymorph of Claim 1, wherein the polymorph is Form A.
3. The crystalline polymorph of Claim 2, wherein said polymorph has an XRPD pattern substantially the same as Figure 1.
4. The crystalline polymorph of Claim 2, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 20.3.
5. A process for preparing the crystalline polymorph of Claim 2, comprising:
 - (a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 1:1 EtOH:water; and
 - (b) recrystallizing the solid to prepare Form A.
6. The crystalline polymorph of Claim 1, wherein the polymorph is Form B.
7. The crystalline polymorph of Claim 6, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 9.9 and 25.5.
8. A process for preparing the crystalline polymorph of Claim 6, comprising:
 - (a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E with a solvent selected from MeOH, or
 - (a2) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from MeOH, acetone and DCM, or
 - (a3) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with a solvent selected from EtOH, or
 - (a4) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with a solvent selected from IPA,
 - (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and the solvent, and

- (c) recrystallizing the solid to prepare Form B; or
 - (d1) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN, or
 - (d2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF, and
 - (e) recrystallizing the solid to prepare Form B; or
 - (f) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol, and
 - (g) recovering the solid to prepare Form B.
9. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Methanol.
10. The crystalline polymorph of Claim 9, wherein said polymorph has an XRPD pattern substantially the same as Figure 2.
11. The crystalline polymorph of Claim 9, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 10.0.
12. A process for preparing the crystalline polymorph of Claim 6, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine with MeOH;
 - (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOH; and
 - (c) recrystallizing the solid to prepare Form B Methanol.
13. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Ethanol.
14. The crystalline polymorph of Claim 13, wherein said polymorph has an XRPD pattern substantially the same as Figure 3.
15. The crystalline polymorph of Claim 13, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 25.4.
16. A process for preparing the crystalline polymorph of Claim 13, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form C/G mixture with EtOH;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOH; and

(c) recrystallizing the solid to prepare Form B Ethanol.

17. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Isopropyl Alcohol.

18. The crystalline polymorph of Claim 17, wherein said polymorph has an XRPD pattern substantially the same as Figure 4.

19. The crystalline polymorph of Claim 17, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 16.9.

20. A process for preparing the crystalline polymorph of Claim 17, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A with IPA;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and IPA; and

(c) recrystallizing the solid to prepare Form B Isopropyl Alcohol.

21. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Acetonitrile.

22. The crystalline polymorph of Claim 21, wherein said polymorph has an XRPD pattern substantially the same as Figure 5.

23. The crystalline polymorph of Claim 21, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 25.7.

24. A process for preparing the crystalline polymorph of Claim 21, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and ACN; and

(b) recrystallizing the solid to prepare Form B Acetonitrile.

25. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Acetone.

26. The crystalline polymorph of Claim 25, wherein said polymorph has an XRPD pattern substantially the same as Figure 6.

27. The crystalline polymorph of Claim 25, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 9.9.

28. A process for preparing the crystalline polymorph of Claim 25, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and acetone; and

(c) recrystallizing the solid to prepare Form B Acetone.

29. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Dichloromethane.

30. The crystalline polymorph of Claim 29, wherein said polymorph has an XRPD pattern substantially the same as Figure 7.

31. The crystalline polymorph of Claim 29, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 16.9.

32. A process for preparing the crystalline polymorph of Claim 29, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM;

(b) creating a solution with the *N*4-(4-[1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DCM; and

(c) recrystallizing the solid to prepare Form B Dichloromethane.

33. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Tetrahydrofuran.

34. The crystalline polymorph of Claim 33, wherein said polymorph has an XRPD pattern substantially the same as Figure 8.

35. The crystalline polymorph of Claim 33, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 25.4.

36. A process for prepping the crystalline polymorph of Claim 33, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and THF; and

(b) recrystallizing the solid to prepare Form B Tetrahydrofuran.

37. The crystalline polymorph of Claim 6, wherein the polymorph is Form B Anhydrous.

38. The crystalline polymorph of Claim 37, wherein said polymorph has an XRPD pattern substantially the same as Figure 9.

39. The crystalline polymorph of Claim 37, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.9.

40. A process for preparing the crystalline polymorph of Claim 37, comprising:

(a) heating *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B; and

(b) recovering the solid to prepare Form B Anhydrous.

41. The crystalline polymorph of Claim 1, wherein the polymorph is Form C.

42. The crystalline polymorph of Claim 41, wherein said polymorph has an XRPD pattern substantially the same as Figure 10.

43. The crystalline polymorph of Claim 41, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 5.0.

44. A process for preparing the crystalline polymorph of Claim 41, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and 2-methoxyethanol;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(c) recrystallizing the solid to prepare Form C.

45. The crystalline polymorph of Claim 1, wherein the polymorph is Form D.

46. The crystalline polymorph of Claim 45, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 8.0 and 12.7.

47. A process for preparing the crystalline polymorph of Claim 45, comprising:

(a1) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from EtOAc, dioxane and propyl acetate, or

(a2) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and a solvent selected from acetone and propyl acetate, and

(b) recrystallizing the solid to prepare Form D.

48. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Ethyl Acetate.

49. The crystalline polymorph of Claim 48, wherein said polymorph has an XRPD pattern substantially the same as Figure 11.

50. The crystalline polymorph of Claim 48, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

51. A process for preparing the crystalline polymorph of Claim 48, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and EtOAc; and

(b) recrystallizing the solid to prepare Form D Ethyl Acetate.

52. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Dioxane.

53. The crystalline polymorph of Claim 52, wherein said polymorph has an XRPD pattern substantially the same as Figure 12.

54. The crystalline polymorph of Claim 52, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 19.5.

55. A process for preparing the crystalline polymorph of Claim 52, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and dioxane; and

(b) recrystallizing the solid to prepare Form D Dioxane.

56. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Acetone.

57. The crystalline polymorph of Claim 56, wherein said polymorph has an XRPD pattern substantially the same as Figure 13.

58. The crystalline polymorph of Claim 56, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

59. A process for preparing the crystalline polymorph of Claim 56, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and acetone; and

(b) recrystallizing the solid to prepare Form D Acetone.

60. The crystalline polymorph of Claim 45, wherein the polymorph is Form D Propyl Acetate.

61. The crystalline polymorph of Claim 60, wherein said polymorph has an XRPD pattern substantially the same as Figure 14.

62. The crystalline polymorph of Claim 60, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 8.0.

63. A process for preparing the crystalline polymorph of Claim 60, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and propyl acetate; and

(b) recrystallizing the solid to prepare Form D Propyl Acetate.

64. The crystalline polymorph of Claim 1, wherein the polymorph is Form E.

65. The crystalline polymorph of Claim 64, wherein said polymorph has an XRPD pattern substantially the same as Figure 15.

66. The crystalline polymorph of Claim 64, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.1.

67. A process for preparing the crystalline polymorph of Claim 64, comprising:

(a) mixing 1-(4-((4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)amino)quinazolin-6-yl)-3-(1-hydroxy-2-methylpropan-2-yl)thiourea in THF under basic conditions;

(b) adding water to the mixture to form an oil of *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine;

(c) recovering the product as *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E.

68. The crystalline polymorph of Claim 1, wherein the polymorph is Form F.

69. The crystalline polymorph of Claim 68, wherein said polymorph has an XRPD pattern substantially the same as Figure 16.

70. The crystalline polymorph of Claim 68, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 16.6.

71. A process for preparing the crystalline polymorph of Claim 68, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E and ethyl acetate; and
 - (b) recrystallizing the solid to prepare Form F.
72. The crystalline polymorph of Claim 1, wherein the polymorph is Form G.
73. The crystalline polymorph of Claim 72, wherein said polymorph is characterized by XRPD diffraction peaks (2θ degrees $\pm$ 0.3) at about 7.8 and 23.2.
74. A process for preparing the crystalline polymorph of Claim 72, comprising:
- (a1) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water, or
 - (a2) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a solvent selected from isopropyl acetate and MIBK, and
 - (b) recrystallizing the solid to prepare Form G; or
 - (c) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran,
 - (d) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF, and
 - (e) recrystallizing the solid to prepare Form G.
75. The crystalline polymorph of Claim 72, wherein the polymorph is Form G hemi-Tetrahydrofuran.
76. The crystalline polymorph of Claim 75, wherein said polymorph has an XRPD pattern substantially the same as Figure 17.
77. The crystalline polymorph of Claim 75, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.1.
78. A process for preparing the crystalline polymorph of Claim 75, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G mono-Tetrahydrofuran and 20:80 THF:water; and
 - (b) recrystallizing the solid to prepare Form G hemi-Tetrahydrofuran.

79. The crystalline polymorph of Claim 72, wherein the polymorph is Form G mono-Tetrahydrofuran.

80. The crystalline polymorph of Claim 79, wherein said polymorph has an XRPD pattern substantially the same as Figure 18.

81. The crystalline polymorph of Claim 79, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.1.

82. A process for preparing the crystalline polymorph of Claim 79, comprising:

- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form A and tetrahydrofuran;
- (b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

- (c) recrystallizing the solid to prepare Form G mono-Tetrahydrofuran.

83. The crystalline polymorph of Claim 72, wherein the polymorph is Form G Isopropyl Acetate.

84. The crystalline polymorph of Claim 83, wherein said polymorph has an XRPD pattern substantially the same as Figure 19.

85. The crystalline polymorph of Claim 83, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.4.

86. A process for preparing the crystalline polymorph of Claim 83, comprising:

- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and isopropyl acetate; and
- (b) recrystallizing the solid to prepare Form G Isopropyl Acetate.

87. The crystalline polymorph of Claim 72, wherein the polymorph is Form G Methyl Isobutyl Ketone.

88. The crystalline polymorph of Claim 87, wherein said polymorph has an XRPD pattern substantially the same as Figure 20.

89. The crystalline polymorph of Claim 87, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 23.3.

90. A process for preparing the crystalline polymorph of Claim 87, comprising:

- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-

(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MIBK; and

(b) recrystallizing the solid to prepare Form G Methyl Isobutyl Ketone.

91. The crystalline polymorph of Claim 1, wherein the polymorph is Form H.

92. The crystalline polymorph of Claim 91, wherein said polymorph has an XRPD pattern substantially the same as Figure 21.

93. The crystalline polymorph of Claim 91, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 11.2.

94. A process for preparing the crystalline polymorph of Claim 91, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MTBE; and

(b) recrystallizing the solid to prepare Form H.

95. The crystalline polymorph of Claim 1, wherein the polymorph is Form I.

96. The crystalline polymorph of Claim 95, wherein said polymorph has an XRPD pattern substantially the same as Figure 22.

97. The crystalline polymorph of Claim 95, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 7.2.

98. A process for preparing the crystalline polymorph of Claim 95, comprising:

(a) mixing amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and xylene; and

(b) recrystallizing the solid to prepare Form I.

99. The crystalline polymorph of Claim 1, wherein the polymorph is Form J.

100. The crystalline polymorph of Claim 99, wherein said polymorph has an XRPD pattern substantially the same as Figure 23.

101. The crystalline polymorph of Claim 99, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 17.0.

102. A process for preparing the crystalline polymorph of Claim 99, comprising:

(a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and 2-methoxyethanol; and

(b) recrystallizing the solid to prepare Form J.

103. The crystalline polymorph of Claim 1, wherein the polymorph is Form K.
104. The crystalline polymorph of Claim 103, wherein said polymorph has an XRPD pattern substantially the same as Figure 24.
105. The crystalline polymorph of Claim 103, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 22.8.
106. A process for preparing the crystalline polymorph of Claim 103, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and DME; and
 - (b) recrystallizing the solid to prepare Form K.
107. The crystalline polymorph of Claim 1, wherein the polymorph is Form L.
108. The crystalline polymorph of Claim 107, wherein said polymorph has an XRPD pattern substantially the same as Figure 25.
109. The crystalline polymorph of Claim 107, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 17.0.
110. A process for preparing the crystalline polymorph of Claim 107, comprising:
- (a) mixing either *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form E or amorphous *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and MeOAc; and
 - (b) recrystallizing the solid to prepare Form L.
111. The crystalline polymorph of Claim 1, wherein the polymorph is Form M.
112. The crystalline polymorph of Claim 111, wherein said polymorph has an XRPD pattern substantially the same as Figure 26.
113. The crystalline polymorph of Claim 111, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees $\pm$ 0.2) at about 9.0.
114. A process for preparing the crystalline polymorph of Claim 111, comprising:
- (a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and 1:1 THF:water; and
 - (b) recrystallizing the solid to prepare Form M.
115. The crystalline polymorph of Claim 1 wherein the polymorph is Form N.

116. The crystalline polymorph of Claim 115, wherein said polymorph has an XRPD pattern substantially the same as Figure 27.

117. The crystalline polymorph of Claim 115, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 22.9.

118. A process for preparing the crystalline polymorph of Claim 115, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form B Ethanol and a solution of 1% sodium carboxymethyl cellulose, 0.1% Tween® in water; and

(b) recrystallizing the solid to prepare Form N.

119. The crystalline polymorph of Claim 1, wherein the polymorph is Form O.

120. The crystalline polymorph of Claim 119, wherein said polymorph has an XRPD pattern substantially the same as Figure 28.

121. The crystalline polymorph of Claim 119, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 11.2.

122. A process for preparing the crystalline polymorph of Claim 119, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G hemi-Tetrahydrofuran with THF;

(b) creating a solution with the *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and THF; and

(c) recrystallizing the solid to prepare Form O.

123. The crystalline polymorph of Claim 1, wherein the polymorph is Form P.

124. The crystalline polymorph of Claim 123, wherein said polymorph has an XRPD pattern substantially the same as Figure 29.

125. The crystalline polymorph of Claim 123, wherein said polymorph is characterized by at least one specific XRPD diffraction peak (2θ degrees ± 0.2) at about 23.5.

126. A process for preparing the crystalline polymorph of Claim 123, comprising:

(a) mixing *N*4-(4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)-3-methylphenyl)-*N*6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Form G Tetrahydrofuran with water; and

(b) recrystallizing the solid to prepare Form P.

127. A pharmaceutical composition comprising a compound of Claim 1, and a pharmaceutically acceptable carrier or excipient.